吡柔比星对减轻非霍奇金淋巴瘤患者化疗骨髓抑制临床意义分析.docVIP

吡柔比星对减轻非霍奇金淋巴瘤患者化疗骨髓抑制临床意义分析 　　摘要：目的： 分析吡柔比星对减轻非霍奇金淋巴瘤化疗患者骨髓抑制的预防作用及临床疗效。方法： 选择我院2011年2月～2014年8月82例非霍奇金淋巴瘤患者，按患者住院号的奇偶性，将其分为对照组和观察组，每组各41例。观察组采用以吡柔比星为主的化疗方案，对照组采用以阿霉素为主的化疗方案。对比分析两组化疗疗效、骨髓抑制及并发症情况。结果： ①对照组总有效率为51.22%，显著低于观察组87.80%（P0.01）。②化疗结束1周后，观察组血小板计数、血红蛋白水平及白细胞计数分别为（92.23±16.40）×109、（85.61±12.57）g/L及（3.53±1.05）×109，均明显高于对照组（52.36±20.11）×109、（72.32±8.02）g/L及（1.95±1.10）×109（P0.01）。③对照组重度贫血8例，严重肺感染8例，重度粒细胞缺乏11例，并发症发生率为65.85%；观察组重度贫血2例，严重肺感染4例，重度粒细胞缺乏4例，并发症发生率为24.39%；观察组并发症发生率更低（P0.01）。结论：采用吡柔比星治疗非霍奇金淋巴瘤具有临床疗效好，骨髓抑制作用轻，严重并发症少等优点，值得临床推广应用。 　　关键词：吡柔比星；恶性淋巴瘤；骨髓抑制；影响 　　Abstract： Objective： To analyze the prevention effects and clinical curative effects of pirarubicin on bone marrow suppression of patients with non-hodgkin lymphoma （NHL） in chemotherapy. Methods： 82 cases of NHL patients were selected from our hospital from February 2011 to August 2014. And the patients were divided into the control group （n=41） and the observation group （n=41） according to the parity of the patients’ admission numbers. The observation group was given pirarubicin-based chemotherapy while the control group was given adriamycin-based chemotherapy. The two groups were compared and analyzed in curative effect of chemotherapy， bone marrow suppression and complications. Results： （1） The total effective rate was 51.22% in the control group， which was significantly less than that of observation group （87.80%） （P0.01）. （2） After 1 week of chemotherapy， platelet， hemoglobin and white blood cell of the observation group were （92.23±16.40）×109， （85.61±12.57）g/L and （3.53±1.05）×109， which were obviously higher than those of the control group （（52.36±20.11）×109， （72.32±8.02）g/L and （1.95±1.10）×109， respectively） （P0.01）. （3） In the control group， 8 cases occurred severe anemia， 8 cases occurred severe pulmonary infection and 11 cases occurred severe agranulocytosis， with the incidence of complications of 65.85%； while in the observation group， 2 cases occurred severe anemia， 4 cases occurred sever